| |
Antibodies are a crucial reagent in R&D, diagnostics, & therapeutics. Download the eBook to learn how you can apply custom antibodies in your work.
|
|
Today's Big NewsDec 13, 2022 |
| By Nick Paul Taylor Merck & Co. has shown why it bet $250 million on Moderna’s mRNA cancer immunotherapy. Weeks after Merck opted into the program, the partners have revealed the personalized candidate reduced the risk of recurrence or death by 44% when given to melanoma patients in combination with Keytruda. |
|
|
|
By Zoey Becker As the year wraps up, Eli Lilly has set high ambitions for the year ahead. As the diabetes launch Mounjaro gains steam, the company says it expects total revenues to exceed $30 billion next year. |
By Heather Landi Amid a weakening macroeconomic environment and ongoing pressure by private and public payers to reduce healthcare costs, a growing number of healthcare companies are faced with credit rating downgrades and potential defaults. |
By Andrea Park Joining Tandem on its bicycle built for two is AMF Medical, the Swiss developer of a patch pump for automated insulin delivery. |
|
If the clinical supply chain is poorly managed, sponsors can struggle to cope with the complexities, causing issues. This playbook covers keys to identifying the need to implement an eClinical Supply Chain Management platform. Download now.
|
|
By James Waldron While more pharmas big and small are pursuing “off-the-shelf” CAR-T therapies, Novartis has been blazing its own trail. The Swiss drugmaker has been fine-tuning its T-Charge platform to speed up the process by ensuring most of the CAR T-cell expansion occurring within the patient’s body. |
By Ben Adams Medtech giant Abbott along with the Brain Injury Association of America is joining forces with actress Rebel Wilson to boost the “invisible injury” that is concussion. |
By Frank Diamond New research to be unveiled at an AMA conference argues that nurse practitioners drive up costs and drive down quality in emergency departments. The president of the American Association of Nurse Practitioners begs to differ. |
By Andrea Park HistoSonics' noninvasive ablation technology directs focused ultrasound toward targeted tissue from outside the body. The company is focusing first on attacking tumors in the liver. |
By Max Bayer Novartis is touting expanded phase 3 data of its rare blood disease med after an initial readout showed significant benefits compared to a couple of AstraZeneca assets. Citing the data, a top Novartis development executive said in an interview that the results support full approval from regulators. |
By Fraiser Kansteiner While Wegovy still hasn’t made its way to the U.K., the obesity med did launch in Novo Nordisk's home market of Denmark Monday, a company spokesperson said over email. |
By Nick Paul Taylor Nimbus Therapeutics’ midphase psoriasis data have persuaded Takeda that the biotech’s TYK2 inhibitor will be big. How big? $4 billion upfront and more again on the back end big. |
By Robert King CMS proposed a cap on the number of nonstandardized Affordable Care Act plans insurers can offer on HealthCare.gov and other updates to network adequacy standards. |
By Angus Liu A clinical trial that started before the first FDA approval for Blincyto might support a new use for the Amgen therapy in acute lymphoblastic leukemia. |
By Andrea Park The FDA isn’t the only one with its eye on Cardiosense’s artificial intelligence algorithms, which are aiming to predict heart disease before it develops. |
Fierce podcastsDon't miss an episode |
| This week on “The Top Line,” we discuss the latest from the Clinical Trials on Alzheimer’s Disease conference. Plus, we cover the week's news including an investigation into Neuralink, Google’s DeepMind and why things aren't working out for PI3Ks. |
|
|---|
|
|
|
Wednesday, January 25, 2023 | 11am ET / 8am PT This webinar, presented by AmerisourceBergen, will deliver insights to manufacturers and payers covering the need for education and best practices for increasing biosimilar adoption, current product landscape and upcoming product launches, and more. Register now.
|
|
| VideoRevolutionize your monoclonal antibody (mAb) manufacturing with expert insights. Sponsored by: Gibco |
| WhitepaperLearn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
| Executive Summary Strategies to help scale-up for commercial manufacturing are critical to getting cell and gene therapies to patients as more advanced therapies reach late-stage clinical studies and regulatory decisions. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| |
|
